GH Research (GHRS) Projected to Announce Earnings on Thursday

Key Points

• GH Research is expected to report Q3 2026 earnings before markets open Thursday, November 5, with analysts forecasting a loss of $0.3122 per share. The earnings call is scheduled for November 6 at 12:30 p.m. ET.
• The company reported a Q2 loss of $0.23 per share, beating consensus expectations for a $0.29 loss. Analysts project losses of $1.20 per share for the current fiscal year and $2.10 for the next.
• Wall Street’s outlook remains generally positive, with a consensus “Moderate Buy” rating and a $45 target price, though one firm maintains a sell rating. GH Research is developing psychedelic-based treatments, including its lead candidate GH001 for treatment-resistant depression.

GH Research (NASDAQ:GHRS - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect GH Research to announce earnings of ($0.3122) per share for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 12:30 PM ET.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.06. On average, analysts expect GH Research to post ($1.20) EPS for the current fiscal year and ($2.10) EPS for the next fiscal year.

GH Research Stock Up 3.4%

GHRS opened at $20.71 on Thursday. GH Research has a 52 week low of $12.04 and a 52 week high of $31.44. The business has a fifty day simple moving average of $24.38 and a 200-day simple moving average of $21.44. The firm has a market cap of $1.42 billion, a P/E ratio of -20.71 and a beta of 1.32.

Wall Street Analysts Forecast Growth

GHRS has been the topic of several research reports. Guggenheim increased their target price on GH Research from $34.00 to $40.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Zacks Research raised GH Research from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 13th. Needham & Company LLC lifted their target price on GH Research from $32.00 to $39.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of GH Research in a research note on Thursday, October 15th. Finally, Cantor Fitzgerald increased their price target on shares of GH Research from $35.00 to $40.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $45.00.

About GH Research

GH Research plc is a clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological disorders. The company is headquartered in Dublin, Ireland, and conducts research and clinical development activities through its proprietary pipeline of psychedelic-based medicines.

Its lead program, GH001, is an investigational inhaled formulation of mebufotenin, also known as 5-MeO-DMT. GH Research has studied GH001 in patients with treatment-resistant depression, with the aim of developing a rapidly acting treatment that may provide meaningful improvements following a short course of administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.